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 Bioconcentration factors of 9 phar-
maceuticals in G. pulex ranged from
0 to 73 L kg1
 G. pulex are capable of pharmaceu-
tical biotransformation.
 Five pharmaceutical metabolites
were determined up to 94.5 ng g1
 Biotransformation can affect BCFtotal
estimates if metabolites are not
accounted for.
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a b s t r a c t
Methods were developed to assess uptake and elimination kinetics in Gammarus pulex of nine phar-
maceuticals (sulfamethazine, carbamazepine, diazepam, temazepam, trimethoprim, warfarin, metopro-
lol, nifedipine and propranolol) using targeted LC-MS/MS to determine bioconcentration factors (BCFs)
using a 96 h toxicokinetic exposure and depuration period. The derived BCFs for these pharmaceuticals
did not trigger any regulatory thresholds and ranged from 0 to 73 L kg1 (sulfamethazine showed no
bioconcentration). Metabolism of chemicals can affect accurate BCF determination through parameter-
isation of the kinetic models. The added selectivity of LC-MS/MS allowed us to develop conﬁrmatory
methods to monitor the biotransformation of propranolol, carbamazepine and diazepam in G. pulex.
Varying concentrations of the biotransformed products; 4-hydroxypropranolol sulphate, carbamazepine-
10,11-epoxide, nordiazepam, oxazepam and temazepam were measured following exposure of the
precursor compounds. For diazepam, the biotransformation product nordiazepam was present at higher
concentrations than the parent compound at 94 ng g1 dw. Overall, the results indicate that pharma-
ceutical accumulation is low in these freshwater amphipods, which can potentially be explained by the
rapid biotransformation and excretion.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Extensive research into organic environmental micropollutants
has enabled the elucidation of the mechanisms for the uptake and* Corresponding author.
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accumulation in biota (Barber et al., 1988, 1991; Mackay and Fraser,
2000). Uptake was mainly considered to occur by passive diffusion
across cellular membranes and traditional models relied heavily on
physico-chemical properties such as octanol-water partition co-
efﬁcients (logP) to describe and predict xenobiotic concentrations
in biota (Kanazawa, 1981; Neely et al., 1974; Veith et al., 1979). Such
earlier works often focussed on neutral compounds (Fu et al., 2009;
Klosterhaus et al., 2013; Wu et al., 2013), but more recently iden-
tiﬁed micropollutant classes, such as pharmaceuticals, are some-
what different in that they are often ionisable and have a wider
range of molecular polarity. Additional mechanisms such as ion
trapping, carrier mediated transport and partitioning to non-lipid
components (protein binding) could also inﬂuence the accumula-
tion of pharmaceutical residues in the environment (Fu et al., 2009;
Klosterhaus et al., 2013; Stott et al., 2015). As most of the reported
work has focussed on vertebrates such as ﬁsh (Gobas et al., 1986;
Kanazawa, 1981; Spacie and Hamelink, 1982; Veith et al., 1979),
the bioaccumulation of compounds in invertebrates is not well
understood.
The OECD 305 guidelines are widely used for estimating the
bioconcentration factor (BCF) or bioaccumulation factor (BAF) in
ﬁsh and have also been applied to invertebrates, such as bivalves
and amphipods (Ashauer et al., 2006, 2010; Meredith-Williams
et al., 2012; OECD; Sordet et al., 2016). Estimations using these
guidelines can be determined using steady-state or kinetic mea-
surements. Kinetic measurement estimates are based on non-linear
regression to generate uptake (k1) and elimination rate constants
(k2) and used together to estimate BCF/BAF. Models assume that
rate constants do not change. However, recent investigations in our
laboratory showed that the OECD model led to signiﬁcant lack-of-
ﬁts for measured data in invertebrates (Miller et al., 2016). The
lack-of-ﬁts were shown to arise from a potentially decreasing k1
trend over time for a proportion of compounds tested. This ﬁnding
was signiﬁcant as such models could lead to under/over estimation
of BCF/BAFs during risk assessment of chemicals in invertebrates.
Possible causes for the decreases in k1 could be related to several
factors such as growth, metabolism and sorption processes. Meta-
bolism in particular, is generally not considered in bioconcentration
studies. Many analytical methods rely on measurement of total
radioactivity of a labelled compound using liquid scintillation
counting (LSC) (Arnot and Gobas, 2006) as an alternative to
conﬁrmatory analytical tools based on liquid chromatography (LC)
or gas chromatography (GC) coupled to mass spectrometry (MS).
However for small freshwater invertebrates, only a few published
LC or GC-MS-based methods exist for parent compound determi-
nation (Grabicova et al., 2015; Inostroza et al., 2016; Miller et al.,
2015; Sordet et al., 2016). A reason for the small number of pub-
lished methods is that sensitivity at environmentally relevant
concentrations is often challenging due to their small size. Simi-
larly, simply increasing the sample mass to be extracted (via
pooling of individuals) is often undesirable due to extra MS signal
suppression or enhancement effects caused by the matrix. There-
fore, a delicate balance is required to ensure sufﬁcient MS sensi-
tivity and that reliable quantiﬁcations can be performed. In the
absence of conﬁrmatory analytical methods, biotransformation
during the exposure period could have a signiﬁcant effect on
invertebrate BCF/BAF estimation using scintillation counting
methods (de Wolf et al., 1992; Oliver and Niimi, 1985; Opperhuizen
and Sijm, 1990). Xenobiotics can also induce or inhibit their own
metabolism or the metabolism of other compounds that will affect
the clearance rate and hence the BCF/BAF (Golan et al., 2011).
Moreover, as standardised methods to measure metabolic products
and the kinetics of biotransformation currently do not exist, it is
difﬁcult to assess the inﬂuence of biotransformation in accumula-
tion (Cowan-Ellsberry et al., 2008). Several authors have applied
in vitro intrinsic clearance rates to extrapolate to whole body
biotransformation rates for predictive BCF modelling (Arnot et al.,
2008; Nichols et al., 2013). However, these extrapolations mea-
sure only the loss of parent compound to predict whole body
biotransformation. Thus, in vitro clearance rates may not reliably
reﬂect whole body metabolic rates (Nichols et al., 2006).
To date only three studies have measured biotransformation
products and their associated toxicokinetics in invertebrates
(Ashauer et al., 2012; Jeon et al., 2013b; R€osch et al., 2016). Two of
these works used LC coupled to high resolution MS (HRMS) or LC
with a radioactivity detector to model the uptake and elimination
proﬁles of organic micropollutants and their biotransformation
products in G. pulex (Ashauer et al., 2012; R€osch et al., 2016).
Ashauer et al. showed that the measurement of biotransformation
improved the accuracy of BCF estimates when compared to esti-
mates using total radioactivity counts (Ashauer et al., 2012). A
further constraint to the study of xenometabolism is that a priori
knowledge of biotransformation products in aquatic organisms is
lacking leading to difﬁculty when developing targeted analytical
methods (Celiz et al., 2009). Current methods have focussed on the
determination of organic pollutants in ﬁsh, with little attention
given to invertebrates or pharmaceutical biotransformation.
Therefore, it is essential that methods are developed that can
determine pharmaceutical biotransformation products to more
reliably assess the affect metabolism has on bioconcentration
models.
The aim of this work was to assess the bioconcentration of a
selection of nine pharmaceuticals in G. pulex using targeted LC-MS/
MS methods described in (Miller et al., 2015). In this regard, the
method developed for pharmaceutical occurrence was used for the
determination of selected known pharmaceutical biotransforma-
tion products of carbamazepine, diazepam and propranolol. The
method showed good performance in terms of linearity, recovery,
precision and robustness. In particular, BCFs were estimated using
the OECD 305 guidelines and kinetic parameters were checked for
constancy over time. Finally, the optimised LC-MS/MS method was
used for the identiﬁcation and determination of biotransformation
products of propranolol, carbamazepine and diazepam. As few
published works have studied pharmaceutical bioconcentration
and biotransformation, the work presented herein addresses the
knowledge gaps concerning their bioaccumulation and biotrans-
formation in invertebrates at environmentally relevant concentra-
tions using a minimised test design.
2. Materials and methods
2.1. Reagents, chemicals and consumables
HPLC grade methanol, acetonitrile, acetone, ethyl acetate,
dichloromethane and dimethyldichlorosiloxane were purchased
from Fischer Scientiﬁc (Loughborough, UK). Analytical grade
ammonium acetate was sourced from Sigma-Aldrich (Dorset, UK).
Propranolol hydrochloride, warfarin, sulfamethazine, carbamaze-
pine, nimesulide, (±)-metoprolol (þ)-tartrate salt, temazepam,
diazepam, nifedipine, oxazepam, nordiazepam, carbamazepine-
10,11-epoxide, and sulfamethazine were all obtained from Sigma-
Aldrich (Steinheim, Germany). Trimethoprim, was ordered from
Fluka (Buchs, Switzerland). Stable isotope-labelled standards
including carbamazepine-d10, propranolol-d7, temazepam-d5 and
diazepam-d5 were ordered from Sigma-Aldrich. Sulfamethazine-d4,
nifedipine-d4, metoprolol-d7, trimethoprim-d3 and warfarin-d5
were ordered from QMX Laboratories (Essex, UK). The propranolol
biotransformation products; 4-hydroxypropranolol, 4-
hydroxypropranolol sulphate and 4-hydroxypropranolol glucuro-
nide were sourced from Santa Cruz Biotechnology (Heidelberg,
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Germany). All pharmaceuticals were of a purity of 97%. Analytical
grade salts (>99%) including sodium hydrogen carbonate, magne-
sium sulphate, calcium sulphate, potassium chloride were pur-
chased from Sigma. Ultra-pure water was obtained from aMillipore
Milli-Q water puriﬁcation system with a speciﬁc resistance of
18.2 MU cm or greater (Millipore, Bedford, MA, USA).
2.2. Sample collection and culture maintenance
Gammarus pulexwere collected by kick-sampling from the River
Cray, South-East London, UK, 5123009.500N 006032.400E. This site
was previously shown to have low pharmaceutical contamination
in both collected surface water and animal samples (Miller et al.,
2015). The populations were transported to the laboratory in
500 mL Nalgene™ ﬂasks ﬁlled with surface water from the sample
collection site. Populations were rinsed with artiﬁcial freshwater
(AFW) and then acclimatised to laboratory conditions (as speciﬁed
below) for a minimum of 7 days before any exposure experiments
were performed. AFW was prepared from 1.15 mM of NaHCO3,
0.50 mM MgSO4, 0.44 mM CaSO4 and 0.05 mM of KCl dissolved in
20 L of ultra-pure water. This water was subsequently aerated for
several hours to remove dissolved carbonic acid and maximise the
dissolved oxygen concentrations. Each culture tank (n ¼ 8) was
ﬁlled with 2.5 L of AFW and animals were fed with either alder or
horse chestnut leaves obtained from the sampling site and condi-
tioned by submersion in surface water for two days prior to use.
2.3. Toxicokinetic exposure and conditions
Toxicokinetic experiments were performed separately for each
pharmaceutical for a total of 96 h which included a 48 h uptake
phase followed by a 48 h depuration period as per (Miller et al.,
2016). Individual adult organisms (n ¼ 25), both male and female
(>5 mg wet weight) were placed in Pyrex glass beakers. G. pulex
were carefully transferred to beakers using blunt forceps to avoid
any harm to the organisms before exposure. Each beaker contained
25 organisms in 200 mL of exposure media (AFW and test com-
pound). G. pulex were exposed to individual pharmaceuticals at a
concentration of 1 mg L1, except for propranolol and warfarin
which were exposed at 10 mg L1. All exposure media contained
<0.001% of organic solvent (methanol). A total of 300 organisms
were used per compound exposure and were sampled for n ¼ 3 per
time-point. Samples were taken at 6, 24, 48 and 96 h across the
toxicokinetic experiments. Negative control exposures were set up
and also sampled at the 96 h time interval. These were subse-
quently analysed for background contamination. The exposure
media was replaced daily and water samples (n ¼ 3) were analysed
at 0 and 24 h after exposure to ensure concentrations of the com-
pounds remained constant in the AFW. Each animal specimen was
rinsed with ultra-pure water and then frozen at 20 C. The light
cycle was 12 h light followed by 12 h dark without a dusk/dawn
transition period. All experiments were performed in a tempera-
ture controlled room at 15 C (±2 C) and water pH was also
monitored across each experiment and measured at an average of
8.19 ± 0.05.
2.4. Sample preparation
Water samples collected from exposure experiments were
ﬁltered using Whatman ﬁlters (0.2 mM) and directly injected onto
the LC-MS/MS for analysis. For G. pulex, A mass of 50 mg of
lyophilised and ground material was extracted by glass bead pul-
verisation in 5 mL of acetonitrile and diluted with 100 mL of
ammonium acetate buffer (10 mM) for loading onto Waters HLB
solid phase extraction (SPE) cartridges (6 cc, 200 mg sorbent). After
loading, samples were eluted using a mixture of ethyl acetate:a-
cetone (50:50 v/v) which was subsequently evaporated under ni-
trogen (99% purity) and reconstituted in 250 mL of starting LC
mobile phase (90:10 v/v, 10 mM ammonium acetate buffer:
acetonitrile).
2.5. Instrumental analysis
Full instrumental conditions were used as per (Miller et al.,
2015). Brieﬂy, separations were performed on an Agilent HP1100
LC system conﬁgured with a Waters SunFire reversed-phase C18
column (150 mm  2.1 mm, 2.5 mM particle size). Following in-
jection (20 mL), elution followed a gradient proﬁle (totalling 75 min
including a 12.5-min re-equilibration time) using a mixture of
acetonitrile and ultra-pure water with 10 mM ammonium acetate.
Detectionwas performed using a Waters Quattro triple quadrupole
mass spectrometer with electrospray ionisation operated in posi-
tive and negative polarity switching mode. Quantiﬁcation of ana-
lytes was performed using 3-point internal standard matrix-
matched calibration using the peak area ratio of non-labelled an-
alyte (precursor range: 50e300 ng g1, biotransformation product
range: 50e150 ng g1) to the stable isotope labelled internal
standard (SIL-IS) (100 ng g1). The exception to this was in the
temazepam exposure where quantiﬁcation was performed against
a SIL-IS calibrant concentration (100 ng g1) by comparing the
response ratio of SIL-IS:unlabelled temazepam. The compounds (4-
hydroxypropranolol sulphate and carbamazepine-10,11-epoxide)
were quantiﬁed using 3-point external matrix-matched calibration
curves due to unavailability of SIL-IS standards.
2.6. Modelling bioconcentration factors
Parameter estimation of uptake rate constant (k1) and depu-
ration rate constant (k2) was performed using a curve ﬁtting algo-
rithm via Minitab statistical software (Minitab Ltd., Coventry UK)
and as outlined in the OECD 305 Fish Bioconcentration Guidelines
(OECD). Full details of parameter estimation can be found in (Miller
et al., 2016). Herein, the authors deﬁne BCFtotal as the summation of
the BCF of both parent/precursor and biotransformation products
(i.e. the total body burden). Whereas, BCFparent will be used to
describe the BCF determined for the parent compound alone.
3. Results and discussion
3.1. Analytical performance and minimised test design evaluation
The previously described analytical method required a sample
mass of 100 mg dw, which corresponded to approximately 40 an-
imals per measurement (Miller et al., 2015). This presented feasi-
bility issues for sampling, maintaining cultures and the scale of
exposure experiments. To mitigate this, 50 mg was used instead
and the reconstitution volume of solvent (post-SPE) was also scaled
down (to 250 mL) to maintain sensitivity. Analytical method per-
formancewas reassessed for 10 pharmaceuticals (See SI, Fig. S1 and
Table S1). In general, imprecision increased with decreasing sample
mass extracted. The use of SIL-IS has been shown to offer improved
precision during analytical method development (Stokvis et al.,
2005). The corresponding SIL-IS for each analyte here also resul-
ted in markedly improved precision for all compounds with % RSDs
ranging from 1 to 11%. Linearity also improved using SIL-IS in
comparison to matrix-matched calibration curves (R2 0.9897).
Therefore, for precise analysis of biota like G. pulex for trace phar-
maceutical residue determination, it is recommended that SIL-IS be
used with LC-MS/MS to overcome precision problems relating to
the limited sample mass available and to enable the number of
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specimens to be minimised.
In addition to the reduction in the number of organisms, a
reduction in the number of sampling time intervals was also
considered. Time points were selected at 6, 24, 48 and 96 h so that
the uptake phase had three time points and the elimination phase
contained two intervals. The additional time point in the uptake
phase was selected so that any losses in k1 constancy could be
highlighted as identiﬁed previously (Miller et al., 2016). The po-
tential limitation when using a small number of time intervals is
that the data may not reﬂect reliably the ability of a compound to
concentrate as modelling is limited to a few data points. The OECD
305 guidelines do propose a minimised test design with two time
intervals in the uptake and elimination phase, respectively (e.g. day
14, 28, 35 & 42). This minimised study design was evaluated
independently in the literature and it was concluded that the test
was valuable and offered reliable BCF estimation for regulatory
purposes (Carter et al., 2014). Springer et al. proposed a second
minimised test design involving only two sampling time intervals
in a 14 d depuration period (Springer et al., 2008). They also found
that minimised test designs were a viable alternative to a full study
design. Given that our experiments here focused on a non-standard
invertebrate species and much shorter uptake and depuration
phases, re-evaluation of the uptake and elimination data from
(Miller et al., 2016) was performed to assess the suitability of a
minimised test design for simultaneous and sequential methods of
BCF estimation in G. pulex (Table S3). An ANOVAwas performed for
each method of estimation and resulted in p-values of 0.95 for
comparison of simultaneous BCFtotal, 0.43 for sequential BCFtotal and
0.45 for sequential BCFtotal determined using linear regression in
the elimination phase data. All three p-values were >0.05 indi-
cating that there were no statistically signiﬁcant differences be-
tween the BCFs estimated by the full study design nor the
minimised design. Therefore, going forward all non-radiolabelled
exposures were performed using the minimised design.
3.2. Toxicokinetic modelling of eight selected pharmaceuticals
Aqueous pharmaceutical concentrations remained stable across
the exposure period for carbamazepine, diazepam, temazepam,
sulfamethazine, metoprolol and trimethoprim (Table 1). Propran-
olol showed stable aqueous concentrations over the ﬁrst 24 h, but
declined by 29% to an average of 6.41 mg L1 thereafter. Nifedipine
showed an average decrease of 39% across both days of the uptake
phase. It is possible that sorption was the cause in the reduction of
nifedipine in the exposure media or could also be attributed to
other transformation processes.
For pharmaceuticals in G. pulex, maximal concentrations after
the uptake phasewere observed for propranolol and likely due to its
higher exposure concentration at 10 mg L1 (due to a relatively high
LOQ value (61 ng g1 dw). In this exposure, internal concentrations
reached 519 ± 143 ng g1 with a mean value of 210 ± 9 ng g1 at the
end of the uptake period. Warfarin also showed relatively higher
concentrations in G. pulex which again was likely explained by the
higher exposure concentration. In contrast to the other studied
compounds, the data for warfarin suggested that it did not reach/
approach steady state in the uptake period as no plateau was
observed in the toxicokinetic proﬁle. The remaining pharmaceuti-
cals carbamazepine, diazepam, metoprolol, nifedipine, trimetho-
prim and temazepam exposed at 1 mg L1 showed internal
concentrations of 51 ng g1 at the end of the uptake phase. These
internal concentrations showed rapid elimination and were
reduced to  LOQ/LOD. The rapid turnover of all pharmaceuticals
suggested that bioaccumulation could be less relevant for these
types of ionisable compounds. BCFs were generated using both
simultaneous and sequential modelling presented in Table 2. The
BCFparent generated for each compound was in the order of
trimethoprim and nifedipine < metoprolol < warfarin
< carbamazepine < propranolol < temazepam < diazepam. The
highest BCFparent generated by the simultaneous method was
41 L kg1 for diazepam and the lowest estimation was 16 L kg1 for
both trimethoprim and nifedipine. These values remain signiﬁ-
cantly lower than any regulatory threshold to be considered bio-
accumulative or very bioaccumulative (European Commission,
2006). The BCFparent values for propranolol and metoprolol were
also compared with the BCFtotal generated previously (Miller et al.,
2016). Propranolol BCFtotal was estimated to be 32 L kg1 and
metoprolol BCFtotal was 16 L kg1, which showed very good agree-
ment with the BCFparent values of 28 and 17 determined by LC-MS/
MS here. Sulfamethazine was not detected in any sample and
therefore indicated that no accumulation in G. pulex had occurred.
Interestingly, exposure to nifedipine (logP ¼ 3.45) resulted in a low
BCF despite it being less polar and was similar to that of trimetho-
prim (logP¼ 1.12). This further suggested that logPwas not a reliable
indicator for BCF of pharmaceuticals and the degree of ionisation
may also play an important role in uptake and bioconcentration
mechanisms. Uptake models have usually been based on neutral
organic micropollutants and is the reason that logP can be a good
indicator of bioconcentration for these compounds especially when
logP is < 6. The logP, logD and predominant form of each pharma-
ceutical exposed to G. pulex is shown in Table S4. Temazepam,
diazepam and carbamazepine remain neutral, but their respective
BCFparent do not followany speciﬁc trendwhen directly compared to
their logP. However, the selection of pharmaceuticals here is limited
and therefore discernible trends may not be apparent. A plot of
logD/P versus estimated BCF showed that therewere no identiﬁable
trends (Fig. S2). Consideration of the complexity of biological
Table 1
Pharmaceutical concentrations in exposure media during the uptake phase. 24 h and 48 h represent the concentration after 24 h of exposure with solutions used on either Day
1 or Day 2.
Compound Concentration (mg L1)
Day 1 (n ¼ 3) SD 24 h (n ¼ 3) SD Day 2 (n ¼ 2) 48 h (n ¼ 3) SD
Carbamazepine 1.12 0.03 1.01 0.05 1.08 1.07 0.02
Diazepam 1.02 0.03 0.86 0.05 1.04 0.89 0.11
Temazepam 0.96 0.03 0.85 0.03 1.17 1.03 0
Nifedipine 0.94 0.09 0.59 0.06 0.82 0.49 0.18
Sulfamethazine 1.06 0.07 0.99 0.17 0.89 0.71 0.15
Trimethoprim 1.09 0.04 1.01 0.11 0.99 0.97 0.04
Metoprolol 0.77 0.18 0.72 0.15 0.86 0.87 0.21
Propranolol 9.22 0.5 8.92 0.29 8.98 6.41a e
Day 1- initial pharmaceutical concentration on day 1.
Day 2- initial pharmaceutical concentration on day 2.
a n ¼ 2
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systems and the unique characteristics of pharmaceuticals, it may
be expected that uptake and bioconcentration is a much more
complex process than can be predicted by a single or small number
of physicochemical properties. Many factors have been proposed
and reported to inﬂuence the bioconcentration of pharmaceuticals
including hydrophobicity, biotransformation, bioavailability, envi-
ronmental exposure scenarios, and carrier mediated uptake
(Barron, 1990). A particularly important factor is the environmental
exposure as the complexity of environmental matrices on BCFsmay
well increase or decrease predicted BCFs or measured BCFs from
in vivo laboratory exposures. Surface water temperature, pH, con-
centrations in sediment and the composition of other components
in the surface water (e.g. complex mixtures including other phar-
maceuticals, colloids, surfactants, organic chemicals etc.) may
directly or indirectly affect the accumulation potential of a com-
pound (Brown et al., 2007; Chen et al., 2017; Nichols et al., 2015).
Few data or reported studies exist on the uptake of pharma-
ceuticals in invertebrates. However, comparison of the BCFparent
estimated here showed good agreement with a study on G. pulex by
Meredith-Williams et al. for two compounds, carbamazepine and
diazepam, (Meredith-Williams et al., 2012). Sordet et al., reported
carbamazepine BCF of 5 L kg1 in Gammarus fossarum which was
~5-fold lower than the BCF determined here (Sordet et al., 2016).
Another study also reported a similar BCF of 51 L kg1 for diazepam
in a marine mussel,Mytilus galloprovincialis (E. Gomez et al., 2012).
In Daphnia magna, BCFs of between 18 and 83 L kg1 for propran-
olol were reported, but the estimated value varied with exposure
concentration (Ding et al., 2016). A review of ﬁsh data generally
revealed low level bioconcentration of the selected pharmaceuti-
cals herein. For example, diazepam BCF in ﬁsh (Ictalurus punctatus)
ranged from 2 to 146 L kg1 depending on the tissue type (Overturf
et al., 2016); sulfamethazine BCF in sturgeons was shown to be
1 L kg1 (Hou et al., 2003); carbamazepine BCF in two species of ﬁsh
(Pimephales notatus and I. punctatus) was <7 L kg1 depending on
tissue (Garcia et al., 2012); and propranolol was also estimated to
have a BCF of <1 L kg1 in Oncorhynchus mykiss and I. punctatus (C.
F. Gomez et al., 2010). These data further support the results herein
and indicate that the selected pharmaceuticals are likely to have a
low potential for bioconcentration in aquatic species.
The model ﬁts of simultaneous and sequential BCFparent esti-
mation showed a signiﬁcant lack-of-ﬁt for several pharmaceuticals
(Fig. 1). Lack-of-ﬁts may arise from a large scatter in the data.
However, the advantage of pooling organisms through LC-MS/MS
measurements is that it reduces scatter of measured internal con-
centrations from single organisms that arises from inter-individual
variability. The lack-of-ﬁt observed seemed to arise from the uptake
phase data and therefore the rate constant was estimated over each
time interval during the uptake period. This revealed that therewas
a decreasing trend in the k1 rate constant which again did not obey
the model's assumptions. Lack-of-ﬁts were observed in the simul-
taneous method of estimation for ﬁve compounds (carbamazepine,
propranolol, metoprolol, warfarin and diazepam) with two com-
pounds showing no signiﬁcant lack-of-ﬁts (temazepam and
trimethoprim). Lack-of-ﬁt for the ﬁnal compound nifedipine was
not possible to estimate due to line that was ﬁt (Fig.1(d)). As several
signiﬁcant lack-of-ﬁts were observed, the k1 rate constant was re-
calculated over the time intervals for the uptake phase data
(Fig. 2). Again, k1 was observed to decrease over time. These de-
creases again are potentially the cause of the lack-of-ﬁts, as sug-
gested previously (Miller et al., 2016). The reason for the decrease in
k1 over time could be attributed to either sorption on to the cuticle
of the animal during the uptake phase, toxicodynamic effects
where the pharmaceuticals are reducing the ability of the organism
to eliminate the compound or growth dilution of the animal.
However, preliminary evidence in (Miller et al., 2016) and the largerTa
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Fig. 1. Toxicokinetic proﬁles of selected pharmaceuticals in G. pulex measured using LC-MS/MS. Solid line represents model ﬁt, dashed lines represent 95% conﬁdence interval. (a)
carbamazepine, (b) diazepam, (c) metoprolol, (d) nifedipine, (e) propranolol, (f) trimethoprim, (g) temazepam and (h) warfarin.
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decreases in k1 at the earlier time interval (this study) suggest that
sorption might be a signiﬁcant cause of the decreases in k1 over
time. In the cases of warfarin, carbamazepine, diazepam and
temazepam an apparent plateau had been reached indicating k1
constancy and it was possible to use this value to estimate the
BCFparent. The average of the k1 over the 48 h time interval for these
compounds resulted in a BCFparent of 20, 26, 40 and 48 L kg1 for
warfarin, carbamazepine, temazepam and diazepam, respectively.
These values showed good agreement between the BCFs generated
by the simultaneous method indicating this could provide an
alternative method for BCF estimation when k1 values are found to
decrease over time. However, it is also possible that steady-state
measurements are more appropriate over kinetic measurements
when estimating pharmaceutical BCFs. Behaviour of pharmaceuti-
cals is also different to more traditional organic pollutants (PAHs,
PCBs, etc.), it appears they often reach steady-state within a rela-
tively short timeframe (~2e3 days) (Meredith-Williams et al., 2012;
Miller et al., 2016). Thus, determination of BCFs using kinetic
parameterisation offers no advantage over the time requirements
for steady-state BCF estimates. Furthermore, steady-state
Fig. 2. Plots of k1 over time for the selected eight pharmaceuticals.
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measurements would also be less resource intensive as they do not
require a depuration period. In addition, the inconsistencies of ki-
netic data as demonstrated here and in (Miller et al., 2016) might
not provide a reliable estimate of BCFs.
3.3. Biotransformation of carbamazepine, diazepam and
propranolol by G. pulex
In addition to their medium to low logP, pharmaceuticals are
designed to bemetabolised and excreted tominimise accumulation
(Kumar and Surapaneni, 2001). As the data suggests, factors other
than hydrophobicity may be important in accumulation, such as
biotransformation, which could also partly explain the variability in
BCFs. Authors have demonstrated that G. pulex are able to metab-
olise a range of organic micropollutants (Ashauer et al., 2012; Jeon
et al., 2013b; R€osch et al., 2016). Conservation of cytochrome P450
enzymes has also been observed in invertebrates (Snyder, 2000)
and pharmaceuticals have been shown to undergo oxidative and
conjugation reactions (Jeon et al., 2013b). As the targeted LC-MS/
MS method only determines the amount of parent compound,
the BCFparent values presented above (Table 2) do not take into
account the accumulation of any biotransformation products. The
biotransformation product half-lives in the body can be longer or
shorter than the parent compound as they are modiﬁed by
biotransformation processes and potentially may lead to increased
or decreased accumulation (Jeon et al., 2013a) and thus will not be
accounted for by estimations of BCFparent.
Selected pharmaceuticals with readily available biotransforma-
tion product reference standards (propranolol, carbamazepine and
diazepam) were used in biotransformation studies and several
transformation products were targeted in the analytical method
including 4-hydroxypropranolol, 4-hydroxypropranolol sulphate,
4-hydroxypropranolol glucuronide, carbamazepine-10,11-epoxide,
oxazepam and nordiazepam and temazepam, the latter of which
was already included in analytical method. A matrix effect and
recovery experiment was performed for these additional analytes
before exposures were performed (SI Table S5). Unfortunately, poor
stability in solution made the matrix effect or recovery assessment
for 4-hydroxypropranolol impossible. This has been reported pre-
viously (Pritchard et al., 1979) and samples required additives
(sodium metabisulﬁte and sodium bisulﬁte) to maintain stability.
Overall, matrix effects were relatively minor for most biotransfor-
mation products ranging from 4% suppression to 9% enhancement.
However the exceptionwas nordiazepamwhich showed 31% signal
suppression. biotransformation products showed acceptable abso-
lute recoveries ranging 82e103% (13% RSD) with the exception of
4-hydroxypropranolol sulphate (34% recovery and 20% RSD) and 4-
hydroxypropranolol glucuronide (no recovery). The lower re-
coveries and precision of these polar conjugates are likely to arise
from poor afﬁnity to the SPE sorbents (HLB) used during sample
preparation. The lower recoveries and precision of these polar
conjugates are likely to arise from poorer afﬁnity to these SPE
sorbents. The use of alternative chemistries including mixed-mode
ion exchangers or dipole bearing polymers may improve the
selectivity for such polar compounds.
Carbamazepine exposures resulted in the detection of carba-
mazepine-10,11-epoxide at 24 h and 48 h in G. pulex. Control or-
ganisms (exposed to AFW only) also showed no detectable peaks
for carbamazepine-10,11-epoxide. This was identiﬁed by a singlem/
z transition (253 / 235) and chromatographic retention time
(within 0.4%). Unfortunately, carbamazepine-10,11-epoxide was
not quantiﬁable as signals were below a signal to noise ratio of 10:1
(Fig. 3). Carbamazepine-10,11-epoxide was not detected at 96 h
suggesting that the biotransformation product may have been
eliminated from the organism by this point. Elimination may either
be via excretion or further biotransformation, e.g. carbamazepine-
10,11ediol is excreted in its free form or as a glucuronic acid con-
jugate in humans (Kudriakova et al., 1992). However, limited data is
available for biotransformation of xenobiotics in invertebrates. A
previous study identiﬁed that carbamazepine was converted to
carbamazepine-10,11-epoxide and was the main metabolic
Fig. 3. SRM transitions for the detected biotransformed products during toxicokinetic
exposures.
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pathway in themussel,Mytilus galloprovincialis (Boillot et al., 2015).
Fish exposed to carbamazepine have also shown the presence of
two carbamazepine biotransformation products, carbamazepine-
10,11-epoxide and 2-hydroxycarbamazepine (Boillot et al., 2015).
For propranolol exposures, 4-hydroxypropranolol sulphate was
conﬁrmed with a single peak transition (356.3 / 276.2) and
chromatographic retention time (within 0.25%) (Fig. 3). HP-SULPH
reached a mean concentration of 75 ± 17 ng g1 dw by the end of
the uptake phase (Fig. 4(a)). The elimination phase showed no
decreases in the concentration 4-hydroxypropranolol sulphate
which was measured at a mean concentration of 84 ± 4 ng g1 dw
at 96 h. Determination of the parent compound propranolol
showed a peak at the 24 h time interval which decreased by 48 h.
Decreases of internal concentrations during the uptake phase are
indicative of active metabolic pathways (Crookes and Brooke,
2011). To the authors’ knowledge, no propranolol biotransforma-
tion products have previously been speciﬁcally identiﬁed using LC-
MS/MS in either ﬁsh or invertebrates. However, from the induced
P450 activity of trout in vivo and in vitro propranolol was suggested
to likely induce its metabolism and it was hypothesised that
biotransformation products may be identiﬁed (Bartram et al.,
2012). More recently trout gill cells have been shown to be
capable of propranolol transport and biotransformation (Stott et al.,
2015), and in carp a range of biotransformation products were
tentatively identiﬁed in vivo using UV methods (Ding et al., 2015).
Furthermore, sulphate conjugates of pharmaceuticals have not
been previously detected in invertebrates. However, previous
works have detected sulphate and glucose conjugates of pyrene in
Daphnia magna (Ikenaka et al., 2006, 2007) and sulphate
conjugates of aldicarb, carbaryl and dichlorophenols in G. pulex
(Ashauer et al., 2012). For biocides (algicides), glutathione conju-
gates have been detected in G. pulex and D. magna (Jeon et al.,
2013b). Finally, G. pulex have also been shown to biotransform
azole fungicides into sulphate, glutathione and glucose-sulphate
conjugates (R€osch et al., 2016). Human trials show that the major
biotransformation products of propranolol were HP and napthox-
ylactic acid (Walle and Gaffney, 1972). The relative importance of
this sulphate conjugation pathway in G. pulex is not known as the
napthoxylactic acid and the glucuronide conjugate could not be
determined. However, some authors have suggested that sulphate
and glucoside conjugation is the major metabolic process in in-
vertebrates for the metabolism of aryl group containing com-
pounds such as propranolol (Ikenaka et al., 2007; Livingstone,
1998).
The ﬁnal exposure was performed with diazepam and all three
selected biotransformation products were detected and quantiﬁed
(Fig. 4(b)). Nordiazepam showed concentrations that reached a
mean concentration of 64 ± 27 ng g1 dw in contrast to temazepam
that reached a maximummean concentration of 6 ± 3 ng g1 dw at
48 h. The 10-fold difference in concentrations suggested that the
biotransformation of diazepam to nordiazepam is the major
metabolic pathway in contrast to the conversion of diazepam to
temazepam. This agrees with mammalian data that shows the
demethylation of diazepam to nordiazepam is the primary meta-
bolic pathway (Umezawa et al., 2008). Temazepam was not
detectable by the 96 h time interval, suggesting this compound had
been either excreted or further biotransformed to oxazepam. The k2
was determined at 0.0194 d1 which is 3-fold lower than the k2 of
diazepam. The estimated half-lives of diazepam and nordiazepam
were 12 h and 36 h, respectively. The difference observed is also in
agreement with the reported half-lives, as nordiazepam has a
longer half-life (50e120 h) than its parent compound diazepam
(44 h) (Umezawa et al., 2008). The k2 of temazepamwas estimated
at 0.016 d1, approximately 4-fold lower than the k2 of temazepam
when exposed to G. pulex as a parent compound. The lower k2 may
be explained by the apparent preferential metabolism of diazepam
to nordiazepam. Thus, enzymes involved in the temazepam
pathway may be less active.
The ﬁnal biotransformation product oxazepam was not detect-
able until 48 h reaching amean concentration of 50 ± 23 ng g1 dw.
The biotransformation of diazepam to either nordiazepam or
temazepam and further conversion to oxazepam would be rate
liming steps leading to the apparent lag phase in the detection of
oxazepam. The k2 estimated for oxazepam was 0.009 d1, with
mean internal concentrations reduced by 21 ng g1 dw over the
48 h depuration period. The half-life determined for oxazepamwas
70 h which is much greater than the reported single or multiple
dose half-life in humans (9e11.6 h) (Greenblatt, 1981). The differ-
ence in half-lives could be due to the continued conversion of
nordiazepam or temazepam to oxazepam after the uptake phase
ended giving an apparent longer half-life. Furthermore, oxazepam
is primarily excreted by conjugation with glucuronide moieties
indicating that G. pulex may not readily metabolise oxazepam as
well as in humans. The degree of accumulation of each biotrans-
formation product is in agreement with Overturf et al., whom
generally found higher concentrations of nordiazepam and oxaz-
epam in comparison to temazepam dependent on the tissue type
(Overturf et al., 2016).
Metabolite enrichment factors (MEFs) can be determined for
biotransformation products (Ashauer et al., 2012). The MEFs can be
likened to a ‘pseudo-BCF’ and further indicate that these
biotransformation products were not accumulative. However,
nordiazepam and oxazepam reached higher internal concentra-
tions relative to the parent compound diazepam. The BCF of
Fig. 4. Determination of biotransformation products (a) Concentration-time proﬁle for
propranolol (solid circles) and 4-hydroxypropranolol sulphate (crosses) in G. pulex. (b)
Concentration-time proﬁle for diazepam (solid circles), nordiazepam (triangles),
oxazepam (squares) and temazepam (crosses) in G. pulex.
T.H. Miller et al. / Chemosphere 183 (2017) 389e400 397
oxazepam has been reported at 22 L kg1 in G. fossarum indicating
that this compound is not accumulative (Sordet et al., 2016).
Furthermore, the summation of the BCFparent and MEFs can give a
BCF that would be comparable to those determined by total
radioactivity counts (i.e. BCFtotal) (Ashauer et al., 2012). For
example, the BCFparent of diazepam ranged from 41 to 58 L kg1
whereas summation of the diazepam BCF and the MEFs would give
a BCFtotal estimate of 165 L kg1. However, it should be considered
that targeted methods will likely only show a small window of the
biotransformation pathways involved with xenobiotic detoxiﬁca-
tion (as in this work). Secondly, targeted methods may not focus on
the important biotransformation products in terms of accumula-
tion, toxicity and elimination. Therefore, untargeted analytical
techniques such as high resolution mass spectrometry (HRMS)
could potentially offer a much greater insight into biotransforma-
tion pathways involved with xenobiotic detoxiﬁcation or identiﬁ-
cation of new compounds (Ashauer et al., 2012; Munro et al., 2015).
However, the quantitative application of LC-HRMS to toxicokinetic
proﬁling needs to be considered carefully, especially where refer-
ence materials for biotransformation products are not available as
discussed previously (Jeon et al., 2013a; R€osch et al., 2016).
Furthermore, studies that only monitor the parent compound by
non-speciﬁc methods should be cautious when reporting BCFs,
especially if there is a high potential for biotransformation. Com-
parison of the total BCF (BCFparent þ MEF) to BCFs determined by
LSC was not possible here. However, Ashauer et al. (2012) reported
that comparison of total BAF and BAF by LSC gave values that were
within a single order of magnitude. However, the differentiation
between biotransformation products and their respective parents
gave better accuracy in parameter estimates (k1/k2) compared to
radioactivity measurements (Ashauer et al., 2012). The reason for
this is that radioactivity measurements can over or underestimate
elimination if biotransformation is not taken into account. As a ﬁnal
consideration, the data presented show that at environmentally
relevant exposure concentrations, pharmaceuticals remain at very
low level concentrations. Furthermore, for the selected compounds
herein, they do not show any signiﬁcant accumulation which has
also been evidenced in the literature by several authors (Boillot
et al., 2015; Meredith-Williams et al., 2012; Miller et al., 2016;
Paterson and Metcalfe, 2008; Sordet et al., 2016). Thus, biotrans-
formation studies will be key in highlighting the behaviour of these
contaminants inside the animal and reveal the role of metabolic
clearance for regulating accumulation. In addition, whilst the
accumulation potential of pharmaceuticals is low, it must now be
considered how these innately low level concentrations of pre-
cursor and biotransformed products will affect the organisms that
are exposed to them. Thus, future work should aim to link accu-
mulation data to effect data for more comprehensive understand-
ing of the potential for adverse outcomes of these emerging
contaminants.
4. Conclusions
As an alternative to traditional LSC approaches, LC-MS/MS was
shown as a suitable technique for the measurement of uptake and
elimination kinetics. The simultaneous BCF estimates ranged from
16 to 41 L kg1 for eight compounds (diazepam, temazepam,
nifedipine, propranolol, metoprolol, carbamazepine, warfarin and
trimethoprim) using the simultaneous model method. Sequential
parameterisation resulted in BCFs of 21e72 L kg1 showing over-
estimates compared to the simultaneous method. Sulfamethazine
showed no bioconcentration in the animals, as no peaks were
detected upon exposure. Models were shown to have signiﬁcant
lack-of-ﬁts for six of the eight pharmaceuticals. The lack-of-ﬁts also
coincided with decreases in the uptake rate constant over time
suggesting that poor model ﬁts may have resulted from this trend.
No trends in bioconcentration were observed with logD or logP,
suggesting factors other than compound hydrophobicity were
important in bioconcentration. The role of metabolism was inves-
tigated for three selected pharmaceuticals (carbamazepine, pro-
pranolol and diazepam). G. pulex were shown to metabolise all
three pharmaceuticals into several different biotransformation
products, indicating the conservation of cytochrome P450 enzymes
in this species. Furthermore, detection of 4-hydroxpropranolol
sulphate indicates the presence of transferases. The ability of
G. pulex to readily metabolise these xenobiotics may explain, in
part, the relatively low BCFs determined for pharmaceuticals in this
work and the literature. Biotransformation pathways and products
were found to be the same between vertebrate data. However,
differences between half-lives were observed for the benzodiaze-
pine compounds (diazepam ¼ 12 h, nordiazepam ¼ 36 h) sug-
gesting that rates of metabolism and elimination are different.
Whilst, kinetics may differ, the same metabolic pathways involved
in elimination mean that human pharmacokinetic data is valuable
for consideration of pharmaceuticals in environmental risk
assessment. Analytical methods that only target and determine the
parent compound in toxicokinetic studies do not measure a BCFtotal.
As MEFs for the diazepam biotransformation products, nordiaze-
pam and oxazepam, showed that some compounds may be more
accumulative than the parent and could potentially be more toxic.
Therefore, it is advisable that targeted MS methods account for
biotransformed products when estimating BCFs.
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